1
|
Wilkinson L and Gathani T: Understanding
breast cancer as a global health concern. Br J Radiol.
95:202110332022. View Article : Google Scholar : PubMed/NCBI
|
2
|
Sancho-Garnier H and Colonna M: Breast
cancer epidemiology. Presse Med. 48:1076–1084. 2019.(In French).
View Article : Google Scholar : PubMed/NCBI
|
3
|
Akram M, Iqbal M, Daniyal M and Khan AU:
Awareness and current knowledge of breast cancer. Biol Res.
50:332017. View Article : Google Scholar : PubMed/NCBI
|
4
|
Ullah MF: Breast cancer: Current
perspectives on the disease status. Adv Exp Med Biol. 1152:51–64.
2019. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kolak A, Kamińska M, Sygit K, Budny A,
Surdyka D, Kukiełka-Budny B and Burdan F: Primary and secondary
prevention of breast cancer. Ann Agric Environ Med. 24:549–553.
2017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Zhang YN, Xia KR, Li CY, Wei BL and Zhang
B: Review of breast cancer pathologigcal image processing. Biomed
Res Int. 2021:19947642021. View Article : Google Scholar : PubMed/NCBI
|
7
|
Varinska L, Gal P, Mojzisova G, Mirossay L
and Mojzis J: Soy and breast cancer: Focus on angiogenesis. Int J
Mol Sci. 16:11728–11749. 2015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Hara Y, Yano H, Yamaguchi R and Iwasaki K:
Surgical excision of a lactating adenoma with rapid enlargement: A
case report. Int J Surg Case Rep. 89:1065442021. View Article : Google Scholar : PubMed/NCBI
|
9
|
Niu J, Ma J, Guan X, Zhao X, Li P and
Zhang M: Correlation between doppler ultrasound blood flow
parameters and angiogenesis and proliferation activity in breast
cancer. Med Sci Monit. 25:7035–7041. 2019. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kumar A, Srivastava V, Singh S and Shukla
RC: Color doppler ultrasonography for treatment response prediction
and evaluation in breast cancer. Future Oncol. 6:1265–1278. 2010.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Braden AM, Stankowski RV, Engel JM and
Onitilo AA: Breast cancer biomarkers: Risk assessment, diagnosis,
prognosis, prediction of treatment efficacy and toxicity, and
recurrence. Curr Pharm Des. 20:4879–4898. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Hasanzadeh M, Solhi E, Jafari M,
Mokhtarzadeh A, Soleymani J, Jouyban A and Mahboob S:
Ultrasensitive immunoassay of tumor protein CA 15.3 in MCF-7 breast
cancer cell lysates and unprocessed human plasma using gold
nanoparticles doped on the structure of mesoporous silica. Int J
Biol Macromol. 120((Pt B)): 2493–2508. 2018. View Article : Google Scholar : PubMed/NCBI
|
13
|
Tang S, Wei L, Sun Y, Zhou F, Zhu S, Yang
R, Huang Y, Zhang H, Xu H and Yang J: CA153 in breast secretions as
a potential molecular marker for diagnosing breast cancer: A meta
analysis. PLoS One. 11:e01630302016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Asif HM, Sultana S, Ahmed S, Akhtar N and
Tariq M: HER-2 positive breast cancer-a mini-review. Asian Pac J
Cancer Prev. 17:1609–1615. 2016. View Article : Google Scholar : PubMed/NCBI
|
15
|
Yaziji H, Goldstein LC, Barry TS, Werling
R, Hwang H, Ellis GK, Gralow JR, Livingston RB and Gown AM: HER-2
testing in breast cancer using parallel tissue-based methods. JAMA.
291:1972–1977. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Grabowska MM and Day ML: Soluble
E-cadherin: More than a symptom of disease. Front Biosci (Landmark
Ed). 17:1948–1964. 2012. View
Article : Google Scholar : PubMed/NCBI
|
17
|
Hu QP, Kuang JY, Yang QK, Bian XW and Yu
SC: Beyond a tumor suppressor: Soluble E-cadherin promotes the
progression of cancer. Int J Cancer. 138:2804–2812. 2016.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Ren H, Shen Z, Shen J and Zhang Y and
Zhang Y: Diagnostic value of Doppler ultrasound parameters combined
with MMP-11 in early breast cancer and benign breast diseases.
Oncol Lett. 20:1028–1032. 2020. View Article : Google Scholar : PubMed/NCBI
|
19
|
Shao Y, Sun X, He Y, Liu C and Liu H:
Elevated levels of serum tumor markers CEA and CA15-3 are
prognostic parameters for different molecular subtypes of breast
cancer. PLoS One. 10:e01338302015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zeiwar MM, Zaki SM, Mohammad LA, Zidan AA
and El Nagar MR: HER-2 gene amplification, serum nucleosomes, CEA
and CA15.3 tumor markers in breast cancer patients. Egypt J
Immunol. 14:29–41. 2007.PubMed/NCBI
|
21
|
Tan PH, Ellis I, Allison K, Brogi E, Fox
SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, et al: WHO
classification of tumours editorial board. The 2019 World health
organization classification of tumours of the breast.
Histopathology. 77:181–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
22
|
Leng X, Huang G, Li S, Yao M, Ding J and
Ma F: Correlation of breast cancer microcirculation construction
with tumor stem cells (CSCs) and epithelial-mesenchymal transition
(EMT) based on contrast-enhanced ultrasound (CEUS). PLoS One.
16:e02611382021. View Article : Google Scholar : PubMed/NCBI
|
23
|
Jafari SH, Saadatpour Z, Salmaninejad A,
Momeni F, Mokhtari M, Nahand JS, Rahmati M, Mirzaei H and Kianmehr
M: Breast cancer diagnosis: Imaging techniques and biochemical
markers. J Cell Physiol. 233:5200–5213. 2018. View Article : Google Scholar : PubMed/NCBI
|
24
|
Bidard FC, Hajage D, Bachelot T, Delaloge
S, Brain E, Campone M, Cottu P, Beuzeboc P, Rolland E, Mathiot C
and Pierga JY: Assessment of circulating tumor cells and serum
markers for progression-free survival prediction in metastatic
breast cancer: A prospective observational study. Breast Cancer
Res. 14:R292012. View
Article : Google Scholar : PubMed/NCBI
|
25
|
Zaleska-Dorobisz U, Kaczorowski K, Pawluś
A, Puchalska A and Inglot M: Ultrasound elastography-review of
techniques and its clinical applications. Adv Clin Exp Med.
23:645–655. 2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Sprague BL, Stout NK, Schechter C, van
Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ,
Miglioretti DL, Mandelblatt JS, et al: Benefits, harms, and
cost-effectiveness of supplemental ultrasonography screening for
women with dense breasts. Ann Intern Med. 162:157–166. 2015.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Bae MS, Seo M, Kim KG, Park IA and Moon
WK: Quantitative MRI morphology of invasive breast cancer:
Correlation with immunohistochemical biomarkers and subtypes. Acta
Radiol. 56:269–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Li F, Li S, Wei L, Liang X, Zhang H and
Liu J: The correlation between pre-operative serum tumor markers
and lymph node metastasis in gastric cancer patients undergoing
curative treatment. Biomarkers. 18:632–637. 2013. View Article : Google Scholar : PubMed/NCBI
|
29
|
Zheng H, Zhong A, Xie S, Wang Y, Sun J,
Zhang J, Tong Y, Chen M, Zhang G, Ma Q, et al: Elevated serum HER-2
predicts poor prognosis in breast cancer and is correlated to
ADAM10 expression. Cancer Med. 8:679–685. 2019. View Article : Google Scholar : PubMed/NCBI
|
30
|
Rochefort P, Chabaud S, Pierga JY, Tredan
O, Brain E, Bidard FC, Schiffler C, Polena H, Khalil-Mgharbel A,
Vilgrain I and Bachelot T: Soluble VE-cadherin in metastatic breast
cancer: An independent prognostic factor for both progression-free
survival and overall survival. Br J Cancer. 116:356–361. 2017.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Lee JS, Park S, Park JM, Cho JH, Kim SI
and Park BW: Elevated levels of serum tumor markers CA 15-3 and CEA
are prognostic factors for diagnosis of metastatic breast cancers.
Breast Cancer Res Treat. 141:477–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
32
|
Laessig D, Nagel D, Heinemann V, Untch M,
Kahlert S, Bauerfeind I and Stieber P: Importance of CEA and CA
15-3 during disease progression in metastatic breast cancer
patients. Anticancer Res. 27((4A)): 1963–1968. 2007.PubMed/NCBI
|
33
|
Di Gioia D, Heinemann V, Nagel D, Untch M,
Kahlert S, Bauerfeind I, Koehnke T and Stieber P: Kinetics of CEA
and CA15-3 correlate with treatment response in patients undergoing
chemotherapy for metastatic breast cancer (MBC). Tumour Biol.
32:777–785. 2011. View Article : Google Scholar : PubMed/NCBI
|
34
|
Zhou BY, Wang LF, Yin HH, Wu TF, Ren TT,
Peng C, Li DX, Shi H, Sun LP, Zhao CK and Xu XH: Decoding the
molecular subtypes of breast cancer seen on multimodal ultrasound
images using an assembled convolutional neural network model: A
prospective and multicentre study. EBioMedicine. 74:1036842021.
View Article : Google Scholar : PubMed/NCBI
|
35
|
McDonald ES, Clark AS, Tchou J, Zhang P
and Freedman GM: Clinical diagnosis and management of breast
cancer. J Nucl Med. 57 Suppl 1:9S–16S. 2016. View Article : Google Scholar : PubMed/NCBI
|
36
|
Song X, Liang B, Wang C and Shi S:
Clinical value of color Doppler ultrasound combined with serum
CA153, CEA and TSGF detection in the diagnosis of breast cancer.
Exp Ther Med. 20:1822–1828. 2020. View Article : Google Scholar : PubMed/NCBI
|
37
|
Thriveni K, Deshmane V, Ramaswamy G and
Krishnamoorthy L: Diagnostic significance of CA15-3 with
combination of HER-2/neu values at 85th percentiles in breast
cancer. Indian J Clin Biochem. 28:136–140. 2013. View Article : Google Scholar : PubMed/NCBI
|
38
|
Brouxhon SM, Kyrkanides S, Teng X,
O'Banion MK, Clarke R, Byers S and Ma L: Soluble-E-cadherin
activates HER and IAP family members in HER2+ and TNBC human breast
cancers. Mol Carcinog. 53:893–906. 2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Grewal DS, Bhanu KU, Sahni H, Maheshwari
S, Kakria N, Mishra PS and Anand V: Role of qualitative
contrast-enhanced ultrasound in the diagnosis of malignant breast
lesions. Med J Armed Forces India. 79:414–420. 2023. View Article : Google Scholar : PubMed/NCBI
|
40
|
Zhao YX, Liu S, Hu YB, Ge YY and Lv DM:
Diagnostic and prognostic values of contrast-enhanced ultrasound in
breast cancer: A retrospective study. Onco Targets Ther.
10:1123–1129. 2017. View Article : Google Scholar : PubMed/NCBI
|
41
|
Lin ZM, Wang TT, Zhu JY, Xu YY, Chen F and
Huang PT: A nomogram based on combining clinical features and
contrast enhanced ultrasound is not able to identify Her-2
over-expressing cancer from other breast cancers. Front Oncol.
13:10356452023. View Article : Google Scholar : PubMed/NCBI
|
42
|
Moelans CB, de Weger RA, Van der Wall E
and van Diest PJ: Current technologies for HER2 testing in breast
cancer. Crit Rev Oncol Hematol. 80:380–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
43
|
Kumari L, Mishra L, Patel P, Sharma N,
Gupta GD and Kurmi BD: Emerging targeted therapeutic strategies for
the treatment of triple-negative breast cancer. J Drug Target.
31:889–907. 2023. View Article : Google Scholar : PubMed/NCBI
|
44
|
Smolanka II, Bagmut IY, Movchan OV,
Sheremet MI, Bilyi OM, Lyashenko AO, Dosenko IV, Loboda AD,
Ivankova OM and Kolisnyk IL: Features of VEGF and IL-6 expression
in patients with inflammatory breast cancer considering
molecular-biological characteristics. J Med Life. 16:153–159. 2023.
View Article : Google Scholar : PubMed/NCBI
|